Oncaspar
Oncaspar ingredients
| Active ingredient | Strength |
|---|---|
| Pegaspargase | 750 [iU]/mL |
What Oncaspar is used for
The FDA lists the approved uses on the official label (below). In the EU, pegaspargase is approved as Oncaspar for:
Oncaspar is indicated as a component of antineoplastic combination therapy in acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years, and adult patients.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Oncaspar
- Generic name
- Pegaspargase
- Made by
- Servier Pharmaceuticals LLC
- Forms
- Injection, Solution
- Given
- Intramuscular, Intravenous
- Drug class
- Asparagine-specific Enzyme
- FDA approval
- Biologic licence (BLA) BLA103411
- On the US market since
- 2020
Official information
- Oncaspar prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Pegaspargase)
In India
- Pegaspargase: 2 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Oncaspar?
Oncaspar (Pegaspargase) is a cancer medicine made by Servier Pharmaceuticals LLC, approved by the US FDA.
What are the ingredients of Oncaspar?
Oncaspar contains Pegaspargase (750 [iU]/mL).
Is Oncaspar approved in Europe?
The same active substance is approved in the EU as Oncaspar.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA